THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 116 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,965,580 | -10.1% | 459,511 | +7.8% | 0.00% | 0.0% |
| Q2 2023 | $4,413,447 | +231.3% | 426,420 | +247.3% | 0.00% | 0.0% |
| Q1 2023 | $1,332,011 | -18.8% | 122,766 | -16.0% | 0.00% | 0.0% |
| Q4 2022 | $1,639,848 | -14.9% | 146,154 | -23.1% | 0.00% | 0.0% |
| Q3 2022 | $1,926,000 | +145.0% | 189,947 | +119.0% | 0.00% | – |
| Q2 2022 | $786,000 | -82.8% | 86,733 | -81.8% | 0.00% | -100.0% |
| Q1 2022 | $4,565,000 | +675.0% | 477,434 | +796.3% | 0.00% | – |
| Q4 2021 | $589,000 | +450.5% | 53,266 | +268.7% | 0.00% | – |
| Q3 2021 | $107,000 | -63.1% | 14,446 | +1.8% | 0.00% | – |
| Q1 2021 | $290,000 | -7.3% | 14,192 | -32.9% | 0.00% | – |
| Q3 2020 | $313,000 | -98.8% | 21,140 | -98.3% | 0.00% | -100.0% |
| Q2 2020 | $25,585,000 | +646.6% | 1,218,912 | +762.5% | 0.02% | +111.1% |
| Q1 2018 | $3,427,000 | +1622.1% | 141,329 | +1235.3% | 0.01% | +800.0% |
| Q1 2016 | $199,000 | – | 10,584 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Link Fund Solutions Ltd | 5,251,349 | $135,459,000 | 69.86% |
| Chescapmanager LLC | 949,006 | $24,570,000 | 3.61% |
| Baupost Group | 9,309,168 | $241,014,000 | 2.66% |
| Rock Springs Capital Management LP | 655,200 | $16,963,000 | 0.54% |
| Rubric Capital Management LP | 173,400 | $4,489,000 | 0.51% |
| Newtyn Management, LLC | 173,300 | $4,487,000 | 0.41% |
| NJ State Employees Deferred Compensation Plan | 38,142 | $988,000 | 0.17% |
| King Wealth Management Group | 22,500 | $583,000 | 0.15% |
| Virtus ETF Advisers LLC | 29,216 | $756,000 | 0.12% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 452,615 | $11,718,000 | 0.12% |